Every 8-K that BrightSpring Health Services, Inc. (BTSG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BTSG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTSG filings page.
BrightSpring Health Services reported strong results for the quarter ended June 30, 2026. Total revenues were $3,873,140 (in thousands), up from $3,147,698, and gross profit rose to $492,746 (in thousands). Operating income increased to $130,391 (in thousands), with income from continuing operations of $86,604 (in thousands) and diluted EPS of $0.38 versus $0.13 a year earlier.
Adjusted EBITDA reached $205,505 (in thousands), compared with $142,517, supported by both segments. In Pharmacy Solutions, prescriptions were stable while revenue per script increased to $314.20 from $257.11 and gross profit per script to $27.50 from $21.54. Provider Services’ home health care average daily census grew to 46,448 from 30,085.
The company increased full-year 2026 guidance to revenues of $15,100 million to $15,425 million and total Adjusted EBITDA of $820 million to $845 million, excluding the Community Living business. Management expects the Amedisys and LHC branches acquisition to contribute about $35 million of Adjusted EBITDA in 2026.
BrightSpring Health Services, Inc. expanded its board of directors from seven to eight members and appointed Dr. Nigam H. Shah as a Class III director on June 11, 2026. He will also serve on the Board’s Quality and Compliance Committee and be compensated under the company’s standard non-employee director policy.
BrightSpring plans to enter into an indemnification agreement with Dr. Shah in the same form used for its other directors and states there are no related-party transactions requiring disclosure. A press release dated June 12, 2026, describing his appointment is furnished as Exhibit 99.1. The company highlights its nationwide home- and community-based pharmacy and health services, serving over 475,000 individuals daily across all 50 states.
BrightSpring Health Services, Inc. entered into an underwriting agreement for an underwritten secondary offering of 14,999,771 shares of its common stock at a public offering price of $58.75 per share. All of these shares were sold by existing selling stockholders, so the company itself did not receive offering proceeds.
In connection with the transaction, BrightSpring repurchased 1,026,465 shares of its common stock from the underwriter as part of the same offering, and the underwriter did not earn underwriting fees on the repurchased shares. The deal was executed under an automatic shelf registration statement on Form S-3ASR and supported by customary representations, covenants, and indemnification obligations among the company, the selling stockholders, and the underwriter.
BrightSpring Health Services, Inc. held its 2026 Annual Meeting of Stockholders, where holders of common stock had one vote per share as of the March 30, 2026 record date. A total of 186,457,085.30 shares were present or represented by proxy, about 96.53% of the voting power.
Stockholders elected three Class II directors, Olivia Kirtley, Max Lin and Steve Miller, to terms expiring at the 2029 annual meeting. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory, non-binding compensation vote for executive officers.
BrightSpring Health Services reported sharply improved first quarter 2026 results and raised its full year outlook. Total revenue reached $3.61 billion for the quarter ended March 31, 2026, compared with $2.88 billion a year earlier, with growth in both products and services.
Net income rose to $148.6 million from $29.0 million, including higher income from continuing and discontinued operations. Adjusted EBITDA increased to $189.8 million, up from $131.1 million, while diluted EPS from continuing operations was $0.34 and Adjusted EPS was $0.39. Operating cash flow strengthened to $122.9 million, and cash and cash equivalents climbed to $888.8 million.
For full year 2026, the company now guides to revenue of $14.7–$15.2 billion and total Adjusted EBITDA of $795–$825 million, both higher than prior 2025 results on a comparable basis. Management expects the Amedysis and LHC acquisition to contribute about $30 million of Adjusted EBITDA in 2026.
BrightSpring Health Services completed the previously announced sale of its Community Living business, including community living services, waiver programs, and intermediate care facilities, to Sevita for aggregate cash consideration of $835 million, subject to customary working capital and other adjustments. A BrightSpring subsidiary, Res-Care, transferred the related assets, equity interests, and liabilities under a purchase agreement signed in January 2025 and amended in December 2025.
BrightSpring’s unaudited pro forma statements show the sale as if it occurred on December 31, 2025, and include an expected $425 million repayment of first lien term loan debt. The estimated after-tax gain on the sale is $31.978 million, with a modest reduction in annual interest expense. Following closing, Robert Barnes, President of ResCare Community Living, resigned and received accelerated vesting of 15,540 restricted stock units and 5,640 stock options; his departure was not due to any disagreement with the company.
BrightSpring Health Services entered an underwriting agreement for an underwritten secondary offering of 20,000,000 shares of common stock at $41.15 per share. All of these shares were sold by KKR and management selling stockholders, so BrightSpring itself did not receive the sale proceeds, other than cash from related stock option exercises.
As part of the same transaction, BrightSpring repurchased 1,464,807 shares of its common stock from the underwriter. The underwriter did not receive underwriting fees on the repurchased shares. The deal was conducted under an automatic shelf registration on Form S-3ASR, with customary representations, covenants, and indemnification provisions.
BrightSpring Health Services, Inc. reported strong fourth quarter and full-year 2025 results and provided full-year 2026 guidance. For 2025, total revenues rose to $12.91 billion from $10.07 billion, driven by growth in both products and services.
Full-year net income improved to $189.1 million from a prior-year loss of $20.5 million, while operating income increased to $295.3 million from $108.0 million. Adjusted EBITDA grew to $617.6 million from $460.2 million, and diluted EPS from continuing operations improved to $0.48 versus a loss of $0.34, with Adjusted EPS rising to $1.00 from $0.35.
In the fourth quarter of 2025, revenue reached $3.55 billion versus $2.75 billion a year earlier, and net income attributable to BrightSpring increased to $77.1 million from $16.0 million. Cash provided by operating activities for 2025 rose sharply to $490.2 million from $23.8 million, supporting business investment and financing outflows.
BrightSpring Health Services, Inc. furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release, dated October 28, 2025, is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will only be incorporated by reference if expressly stated.
BrightSpring Health Services (BTSG) disclosed an underwritten secondary offering of 15,000,000 shares of common stock by selling stockholders, including KKR Phoenix Aggregator L.P., under an automatic shelf on Form S-3ASR. The closing of the offering and related share repurchase occurred on October 22, 2025.
The Company did not receive proceeds from the offering, other than cash received from Management Selling Stockholders’ stock option exercises in connection with the transaction. BrightSpring repurchased 1,500,000 shares from the underwriter as part of the offering, and the underwriter did not receive underwriting fees on the repurchased shares. The underwriting agreement includes customary representations, conditions, and indemnification provisions.
BrightSpring Health Services furnished an 8-K announcing it issued a press release with certain preliminary financial information for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The disclosure under Item 2.02 is expressly treated as furnished, not filed, under the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
BrightSpring Health Services, Inc. (Nasdaq: BTSG) filed an 8-K announcing the immediate resignation of Michael McMaude as President of Hospice Services and CEO of its wholly-owned subsidiary, Abode Healthcare, effective 20 June 2025. The filing states that the departure is not due to any disagreement over operations, policies or practices.
Under a Resignation Agreement (Exhibit 10.1), Mr. McMaude will transition to a non-employee consultant role through the earlier of 26 January 2027 or earlier termination. Key economic terms include:
- Consulting compensation: $2,000 per month plus an additional $12,000 covering the first 45 days, and reimbursement of pre-approved expenses.
- Equity treatment: All outstanding unvested stock options, RSUs, and phantom shares continue to vest while he provides consulting services. Option exercise windows are extended to their original expiration dates.
- Liquidity: Equity purchased at the time of Abode’s acquisition may be sold in tranches beginning on the Effective Date, subject to securities laws.
- Restrictive covenants: Non-compete for the Consulting Period plus one year; non-solicitation and non-hire for the Consulting Period plus two years.
The company emphasizes continuity by retaining Mr. McMaude’s expertise, but his exit removes a senior leader from the hospice segment, which has been an important growth vector for BrightSpring. No other executive changes or financial impacts were disclosed, and no earnings or guidance were provided. Investors should examine whether leadership transition affects the integration and performance of Abode within the broader BrightSpring platform.